Q4 2024 Abeona Therapeutics Inc Earnings Call Transcript
Key Points
- Abeona Therapeutics Inc (ABEO) is anticipating FDA approval for prademagene zamikeracel (pz-cel) for RDEB, with a PDUFA date set for April 29, 2025.
- The company has initiated label discussions with the FDA and received post-marketing commitments, indicating progress in the approval process.
- Abeona has identified a significant commercial opportunity for pz-cel in the US, estimating a potential revenue of over $2 billion.
- The company is preparing for a third-quarter 2025 launch of pz-cel, with five treatment centers in the US undergoing onboarding and activation.
- Abeona has a strong cash position with $98.1 million as of December 31, 2024, providing sufficient financial resources to fund operations into 2026.
- The launch of pz-cel is expected to be supply-constrained initially, with manufacturing capacity ramping up gradually.
- There is a potential backlog of patients due to limited initial manufacturing capacity, which could delay treatment for some patients.
- The company faces challenges in educating physicians and patients about pz-cel, as it is a new treatment option requiring extensive planning and coordination.
- Abeona's general and administrative expenses increased significantly in 2024 due to commercial launch preparation costs.
- The company has not yet finalized plans for international expansion, indicating potential delays in accessing markets outside the US.
Greetings. Welcome to Abeona Therapeutics full year 2024 results and business update conference call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, Greg Gin, VP of Investor Relations, and Communications at Abeona. Greg, you may begin.
Thank you, Paul. Good morning, and thank you for joining us on our full year 2024 results and business update conference call. During this call, we will refer to the press release issued this morning announcing the financial results. It's available on our corporate website at www.abeonatherapeutics.com.
Remarks made during today's call may contain projections and forward-looking statements, which are made pursuant to the Safe Harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change. Actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
